Tyrosine kinase inhibitors as antiangiogenic drugs in multiple myeloma

Domenico Ribatti

Research output: Contribution to journalArticlepeer-review


Tyrosine kinase inhibitors are a new class of anticancer drugs, that are capable of directly interacting with the catalytic site of the target enzyme and thereby inhibiting catalysis. Therapeutically useful tyrosine kinase inhibitors are not specific for a single tyrosine kinase, but rather they are selective against a limited number of tyrosine kinases. The success of imatinib-mesylate (Gleevec®) for the treatment of patients with chronic myeloid leukemia has opened a intensive search for new small molecular compounds able to target other protein tyrosine kinases involved in the malignant transformation. This review article is focused on the use of tyrosine kinase inhibitors as antiangiogenic molecules in the treatment of multiple myeloma.

Original languageEnglish
Pages (from-to)1225-1231
Number of pages7
Issue number4
Publication statusPublished - 2010


  • Angiogenesis
  • Antiangiogenesis
  • Multiple myeloma
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science


Dive into the research topics of 'Tyrosine kinase inhibitors as antiangiogenic drugs in multiple myeloma'. Together they form a unique fingerprint.

Cite this